Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
Sponsor: Liaoning Chengda Biotechnology CO., LTD
Summary
The main objective of this study is to evaluate the persistence of Japanese encephalitis antibodies in participants at the age of 6, after they have followed different Japanese encephalitis vaccination schedules. Furthermore, the study will assess the immunogenicity and antibody persistence of primary immunization across different Japanese encephalitis vaccination schedules, as well as the immunogenicity following booster immunizations within these schedules. The safety of each vaccine dose will also be evaluated.
Key Details
Gender
All
Age Range
8 Months - 8 Months
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2023-11-11
Completion Date
2031-12-31
Last Updated
2025-03-11
Healthy Volunteers
Yes
Conditions
Interventions
Japanese Encephalitis Vaccine (Vero Cell), Inactivated
0.5ml for each dose, manufactured by Liaoning Chengda Biotechnology Co., Ltd., administered in the deltoid area of lateral arm by intramuscular injection.
Japanese Encephalitis Vaccine, Live
0.5ml for each dose, manufactured by Chengdu Institute of Biological Products Co., Ltd., administered subcutaneously in the lower part of the deltoid area of lateral arm.
Locations (6)
Jiashan County Center for Disease Control and Prevention
Jiaxing, Zhejiang, China
Pinghu Center For Disease Control and Prevention
Jiaxing, Zhejiang, China
Dongyang Center for Disease Control and Prevention
Jinhua, Zhejiang, China
Yongkang Center for Disease Control and Prevention
Jinhua, Zhejiang, China
Yuyao Center for Disease Control and Prevention
Ningbo, Zhejiang, China
Jiangshan Center For Disease Control and Prevention
Quzhou, Zhejiang, China